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Spinal and bulbar muscular atrophy is an X-linked motor neuron disease caused by a CAG repeat expansion in the androgen
receptor gene. To characterize the natural history and deﬁne outcome measures for clinical trials, we assessed the clinical
history, laboratory ﬁndings and muscle strength and function in 57 patients with genetically conﬁrmed disease. We also
administered self-assessment questionnaires for activities of daily living, quality of life and erectile function. We found an
average delay of over 5 years from onset of weakness to diagnosis. Muscle strength and function correlated directly with serum
testosterone levels and inversely with CAG repeat length, age and duration of weakness. Motor unit number estimation was
decreased by about half compared to healthy controls. Sensory nerve action potentials were reduced in nearly all subjects.
Quantitative muscle assessment and timed 2min walk may be useful as meaningful indicators of disease status. The direct
correlation of testosterone levels with muscle strength indicates that androgens may have a positive effect on muscle function in
spinal and bulbar muscular atrophy patients, in addition to the toxic effects described in animal models.
Keywords: Kennedy disease; spinal and bulbar muscular atrophy; motor neuron disease; androgens
Abbreviations: ADL=activities of daily living; CI=conﬁdence interval; CMAP=compound motor action potential;
IIEF=International Index of Erectile Function questionnaire; MCS=mental component summary of the SF-36v2; MUNE=motor
unit nerve estimation; NIH=the National Institutes of Health; PCS=physical component summary of the SF-36v2;
QMA=quantitative muscle assessment; SBMA=spinal and bulbar muscular atrophy; SD=standard deviation; SE=standard error;
SF-36v2=Medical Outcomes Study 36-item Short Form Version 2 questionnaire; SNAP=sensory nerve action potential
Introduction
Spinal and bulbar muscular atrophy (SBMA, Kennedy’s disease) is
an X-linked, adult onset motor neuron disease characterized by
slowly progressive weakness of the bulbar and extremity muscles.
SBMA patients may become wheelchair dependent 20–30 years
after onset (Tsukagoshi et al., 1965; Kennedy et al., 1968).
Involvement of bulbar muscles may lead to dysarthria and
dysphagia (Ferrante et al., 1997). Fasciculations often occur,
particularly around the mouth and in the tongue (Ferrante
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and tremor. Other common neurological features include
decreased or absent deep tendon reﬂexes (Antonini et al., 2000)
and sensory loss (Ferrante et al., 1997; Antonini et al., 2000).
SBMA patients also often have signs of androgen insensitivity,
such as gynecomastia and reduced fertility (Dejager et al., 2002).
SBMA is a member of the family of CAG-polyglutamine
expansion diseases that includes Huntington’s disease and seven
spinocerebellar ataxias (Lieberman et al., 2000). Previous studies
of SBMA and the other polyglutamine diseases have shown that
the length of the CAG expansion correlates inversely with age of
disease onset, i.e. the longer the expansion the earlier the onset
(La Spada et al., 1992). In SBMA, CAG repeat length has also
been reported to correlate with motor and sensory nerve conduc-
tion abnormalities (Suzuki et al., 2008).
The SBMA repeat expansion is in the ﬁrst exon of the androgen
receptor gene (La Spada et al., 1991). The androgen receptor is a
nuclear receptor that normally regulates gene expression after
ligand binding. The primary androgen receptor ligands are testos-
terone and dihydrotestosterone. Studies in animal models and
patients indicate that these ligands are important for the develop-
ment of the disease. This evidence includes the following
observations: (i) male transgenic mice expressing the mutant
androgen receptor have a neuromuscular deﬁcit resembling
SBMA and females are much less affected; (ii) when the male
mice are castrated (Chevalier-Larsen et al., 2004) or treated
with the anti-androgen leuprorelin (Katsuno et al., 2002, 2003),
the phenotype is improved, and when female transgenic mice are
given testosterone, the SBMA phenotype becomes fully mani-
fested; (iii) in humans, heterozygous female carriers of the disease
gene are generally asymptomatic, and even homozygous females
in one reported family had only mild symptoms (Sobue et al.,
1993; Schmidt et al., 2002). Together, this evidence supports
the hypothesis that SBMA disease manifestations are primarily
due to a ligand-dependent toxic gain of function in the mutant
androgen receptor.
While the clinical features of SBMA are fairly well known, little
natural history data are available to inform the selection of sample
size, outcome measures, and biomarkers for SBMA intervention
trials (Katsuno et al., 2006). Additional retrospective data would
help to deﬁne the natural history of SBMA and guide the design of
future clinical trials. Here we present an analysis of retrospective
and cross-sectional data collected from 57 patients with SBMA.
Patients and methods
Patients and clinical evaluations
Subjects were recruited to the National Institutes of Health (NIH)
Clinical Research Center in Bethesda, MD for the purpose of partici-
pating in a trial to assess the efﬁcacy and safety of the 5-alpha
reductase inhibitor dutasteride in SBMA. An NIH Institutional Review
Board approved the protocol, and the study was conducted, and
informed consent obtained, in accordance with the principles of the
Declaration of Helsinki. Subject demographics are summarized in
Table 1. Fifty-four subjects were self-identiﬁed as European-
American, two as Asian-American and one as African-American. The
relative lack of ethnic minorities may be due in part to founder effects
in SBMA (Tanaka et al., 1996; Lund et al., 2000) and in part to
recruitment bias. All subjects were clinically and genetically diagnosed
with SBMA before entrance into the study, and genetic conﬁrmation
with repeat length was obtained for each. At the initial screening visit
the subjects underwent a series of tests to characterize their disease
status. Additional natural history information was obtained by a mailed
questionnaire.
Strength and functional testing
Quantitative muscle assessment (QMA), a measure of maximal
voluntary isometric muscle contraction, was done with a ﬁxed frame
dynamometer (strain gauge tensiometer) and computer-aided data
acquisition (The Computer Source, Gainesville, GA). The mean of
three efforts for each muscle group was recorded (Andres et al.,
1996; Mathieu et al., 2003). Normative values were obtained from
a group of 10 healthy men matched with the SBMA subjects for age
and body mass index. In the healthy volunteers, we found inter- and
intra-rater reliability of the QMA testing protocol used in this study to
be very good, with interclass and intraclass correction coefﬁcients of
0.95 and 0.93, respectively.
For the timed walk, we used the 2min walk test, since it is more
feasible than longer tests (Brooks et al., 2007), particularly for
repetitive testing in subjects with ambulatory difﬁculty (Light et al.,
1997), and it can be performed in patients with and without assistive
devices (Rossier et al., 2001). As previously reported, the timed 2min
walk test has high intra- and inter-rater reliability (interclass and
intraclass correction coefﬁcients of 0.97 and 0.98, respectively)
Table 1 Demographics of SBMA patients
MeanSD (range)
Disease milestones (years)
Age at ﬁrst muscle weakness 4110 (18–64)
Age at ﬁrst presentation for medical care 449 (22–64)
Age at clinical diagnosis 479 (29–66)
Age at genetic diagnosis 4710 (29–75)
Age at evaluation for study 5310 (37–79)
Mean intervals between milestones (years)
First muscle weakness to ﬁrst
medical attention
2.2
First muscle weakness to clinical diagnosis 5.5
First muscle weakness to genetic diagnosis 5.9
First muscle weakness to evaluation
for study
11.8
First medical attention to clinical diagnosis 3.1
First medical attention to genetic diagnosis 3.5
Self-assessed activity level
Activity level before disease onset
(1–5, 5 high)
4.60.6 (3–5)
Current activity level (1–5, 5 high) 2.51.1 (1–5)
Genetic
CAG repeat length (number) 46.72.5 (41–53)
Family history
Positive 34
Negative 16
Fifty-seven patients were genotyped, and 45–50 provided information for each
of the other demographic variables.
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(1997), subjects walked back and forth a distance of 50ft for 2min.
The test was repeated three times with an opportunity for the subjects
to rest between trials. The mean distance of the three trials and use of
optional assistive devices were recorded (Table 4).
Neurophysiological studies
Fifty-four SBMA subjects underwent nerve conduction studies and
motor unit number estimation (MUNE). Nerve conduction studies
were done using standard methodology and reported according to
lab normative values (Liveson and Ma, 1992). Four sensory nerves
(median, ulnar, radial and sural nerves) and two motor nerves
(median and peroneal nerves) were studied. Only the right median
and peroneal compound motor action potential (CMAP) values and
right average sensory nerve action potential (SNAP) values were used
for the correlation and regression analyses.
MUNE was performed on a Nicolet Viking Select electromyography
machine using the statistical MUNE program. The MUNE was modiﬁed
by excluding small motor unit potentials under 40mV (Shefner et al.,
2004) to account for greater motor unit instability noted in SBMA
(Lehky et al., 2009). For the SBMA subjects, the MUNE was evaluated
in the right abductor pollicis brevis (n=48); if the right abductor
pollicis brevis was very atrophic and had a very low CMAP, the left
abductor pollicis brevis was also evaluated (n=4). Fourteen healthy
male volunteers for the MUNE were recruited through the Patient
Recruitment and Public Liaison Ofﬁce at the NIH, with informed
consent, and had a similar age distribution to the SBMA subjects
(558 years). In these healthy subjects, the right and left abductor
pollicis brevis MUNEs were evaluated, although abnormal median
CMAPs, deﬁned as CMAP 54.5mV or distal latency 44.5ms were
excluded.
Self-assessment testing
Subjects completed a nine question assessment of ability to perform
speciﬁc activities of daily living (ADL). The ADL assessment was
modiﬁed from the ADL subscale in the Friedreich’s Ataxia Rating
Scale (Subramony et al., 2005) by replacing the question about
bladder function with one about handwriting (0=normal; 1=slightly
slow or small, all words are legible; 2=moderately slow or small, all
words are legible; 3=severely affected, not all words are legible;
4=the majority of words are not legible). Subjects rated each item
from 0 (normal) to 4 (fully impaired) in 0.5 increments. For the data
analysis, the scores were inverted to give a total potential score of
36 (normal).
The subjects also completed the Medical Outcomes Study 36-item
Short Form Version 2 questionnaire (SF-36v2), a 4 week-recall quality
of life assessment that has been widely used previously (Riazi et al.,
2003; Finas et al., 2006). Using the statistical analysis system analysis
code provided by QualityMetric, Inc. (Lincoln, RI), raw scores were
converted into norm-based scores with a mean of 50 and a standard
deviation (SD) of 10 (Ware et al., 2007). The SF-36v2 can be con-
densed into two summary measures: the physical component summary
(PCS) and the mental component summary (MCS). These summary
scores were used in the statistical analysis (Table 7 and Supplementary
Tables 1 and 2), and national norm-based scores from Ware et al.
(2007) were used for comparison with the SBMA population (Table 6).
The 15 question International Index of Erectile Function (IIEF) survey
was used to assess sexual satisfaction and function. The IIEF has been
shown to have good test–retest reliability and discriminant validity
(Rosen et al., 1997, 2002).
Data analysis
Statistical analyses were performed with statistical analysis system
9.1.3 (SAS Institute, Inc., Cary, NC) or SUDAAN 9.0 (Research
Triangle Institute, Inc., Cary, NC). In this study, descriptive statistics
such as mean, SD, standard error (SE), range, and 95% conﬁdence
interval (CI) of mean were used to summarize the quantitative mea-
sures for the SBMA subjects. The national estimates presented in
Table 3 were generated from the 2005–2006 National Health and
Nutrition Examination Survey using weights recommended by the
National Center for Health Statistics (http://www.cdc.gov/nchs/
nhanes/nhanes2005-2006/nhanes05_06.htm) and statistical software
capable of accommodating the complex sampling design of the
national survey (descriptive methods available on request). Either a
one sample or a two sample t-test was used to compare SBMA
patients with published control data, where available. Satterthwaite’s
method was used if necessary. P-values were two-sided, and a level of
signiﬁcance of 0.05 was used.
Spearman’s correlation coefﬁcients were used to assess correlations
between the various measures. For multivariate analysis, stepwise
multiple linear regressions were ﬁrst done to select the best subset
of covariates among age, CAG repeat length, total testosterone, free
testosterone and dihydrotestosterone. As a result, age, CAG repeat
length and total testosterone (not dihydrotestosterone or free testos-
terone) were selected. Depending on the selected subset of
covariates, a simple or multiple linear regression analysis was then
done to assess the inﬂuence of the chosen covariates for each mea-
sure. The analysis was repeated with duration of weakness in place of
age.
Results
Clinical and genetic background
The average age at evaluation for this study was 53 years, and the
average age reported for onset of muscle weakness was 41 years
(Table 1). The average age of diagnosis was 47 years, 5.5 years
after the onset of weakness. There was an average delay of
3.5 years from ﬁrst medical attention to genetic diagnosis.
Fifteen (32%) of 47 respondents reported being misdiagnosed
before the ﬁnal SBMA diagnosis; six of these were misdiagnosed
with amyotrophic lateral sclerosis. As indicated in Table 2, the
most common presenting symptom was muscle cramps (n=22),
followed by tremors and leg weakness (n=16). Half the
patients reported that the weakness was ﬁrst noticeable in the
legs, followed by bulbar symptoms in 33%. The mean CAG
repeat length in the androgen receptor gene was 47 (range 41–
53). Thirty-four (68%) of the subjects had a known positive family
history.
Biochemical and hormonal proﬁles
Biochemical and hormonal proﬁles for 57 subjects are listed in
Table 3. Creatine kinase was elevated in 88% of the patients.
Aspartate and alanine aminotransferases and lactate dehydrogen-
ase were also elevated above the reference range in 72, 60 and
35% of patients, respectively. However, this may not be due to
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not increased compared to national estimates.
Twelve of the 57 SBMA subjects were taking medication to
correct hyperlipidemia. Many subjects had total cholesterol (53%)
and low-density lipoprotein (67%) levels elevated above the recom-
mended levels, with mean levels of 204 and 141mg/dl, respectively.
However, total cholesterol, high-density lipoprotein (HDL), trigly-
ceride and fasting glucose were all similar to control levels reported
by the 2005–2006 National Health and Nutrition Examination
Survey. Only low-density lipoprotein showed signiﬁcant divergence.
The same result was observed when subjects taking hyperlipidae-
mia-correcting medication were excluded.
Serum hormone values were generally within the reference
ranges (Table 3). However, sizeable minorities of subjects had
abnormally low levels of free testosterone or dihydrotestosterone.
The mean SBMA oestradiol levels were elevated compared to the
reference range and to healthy controls. Moreover, when SBMA
androgen levels were compared with age-matched healthy con-
trols (Wu et al., 1995; Litman et al., 2007), a divergence was seen
between SBMA subjects and healthy controls in total testosterone,
free testosterone, dihydrotestosterone, androstenedione and oes-
tradiol levels.
Strength and functional measures
Table 4 summarizes the subjects’ performance on QMA and timed
2min walk (n=56). Compared with healthy controls the subjects
had decreased total (50%), lower extremity (52%) and upper
extremity (47%) composite peak isometric forces as scaled for
body weight. The strength in 11 muscle groups ranged from
38 to 70% of healthy control values. The weakness was asymmetric
(45% left–right difference) in 62% of the subjects, and interestingly
the dominant side was weaker in over two thirds of these (69%).
The average distance covered in the timed 2min walk test was
10950m (range 15–208m). Twenty-two of the 56 subjects
used assistive devices such as canes, walkers, or ankle-foot
orthoses; these covered a mean distance of 6623m, with an
average velocity of 0.55m/s. The mean for 34 subjects who did
not use gait aids was 13644m, with an average velocity of
Table 2 SBMA onset distribution
Number (%)
Presenting symptoms
Bulbar weakness 1 (1)
Arm weakness 5 (7)
Leg weakness 16 (23)
Breast enlargement 5 (7)
Cramps 22 (32)
Tremor 16 (23)
Other 4 (6)
Area of ﬁrst muscle weakness
Bulbar 20 (33)
Arm 10 (17)
Leg 30 (50)
Presenting symptoms were assessed retrospectively for 57 patients at the time of
evaluation. Some patients reported more than one symptom at onset. Numbers
in parentheses indicate percent of total symptoms reported. Presenting symp-
toms noted as ‘‘other’’ include choking, muscle twitching (fasciculations) and
musculoskeletal pain.
Table 3 Serum markers at initial evaluation with percent out of range
SBMA meanSE (range) Reference Out of reference range (%) National estimate for
[95% mean CI] range
Low High
healthy control meanSE
Biochemical proﬁle
Fasting glucose (mg/dl) 1052 (79–189) [101, 109] 70–115 0 12 1092
Creatine kinase (U/l) 1159114 (118–4434) [935, 1382] 52–386 0 88
Total cholesterol (mg/dl) 2045 (125–283) [195, 213] 100–200 0 53 2011
Triglycerides (mg/dl) 18019 (37–850) [143, 217] 1605
High-density lipoprotein (mg/dl) 512 (34–82) [48, 54] 490.4
Low-density lipoprotein (mg/dl) 1414 (66–224) [133, 150] 65–129 0 67 1201
Aspartate aminotransferases (U/l) 462 (24–109) [41, 50] 6–41 0 72 281
Alanine aminotransferases (U/l) 543 (24–111) [49, 60] 9–34 0 60 301
Lactate dehydrogenase (U/l) 2168 (125–373) [201, 231] 113–226 0 35 1291
Gamma glutamyl transferase (U/l) 222 (7–86) [19, 26] 11–52 11 4 403
Hormonal proﬁle
Total testosterone (ng/dl)** 62135 (187–1570) [553, 689] 240–950 4 9 5204
Free testosterone (ng/dl)** 141 (4–26.7) [12, 15] 9–30 14 0 100.1
Dihydrotestosterone (ng/dl)** 453 (4–157) [38, 51] 30–85 28 4 260.4
Androstenedione (ng/dl)* 1009 (41–518) [82, 118] 40–150 0 5 1213
Oestradiol (pg/ml)** 604 (25–163) [52, 68] 520–56 0 39 381
Fasting glucose and creatine kinase reference ranges were set by the NIH Department of Laboratory Medicine (Bethesda, MD); cholesterol and low-density lipoprotein
reference ranges represent desirable and optimal/near optimal ranges, respectively. Serum dihydrotestosterone reference levels are as reported by Esoterix, Inc. (Austin,
TX), and serum oestradiol reference ranges are from the NIH Department of Laboratory Medicine (Bethesda, MD). The remaining serum hormonal ranges area ss e tb y
the Mayo Medical Laboratories (Rochester, MN). National estimates of means and SEs for the biochemical proﬁle were generated from the 2005–2006 National Health
and Nutrition Examination Survey using a nationally representative sample of 1480 men with a mean age of 53.2 years (range 37–79). For the hormonal proﬁle, healthy
control mean values and SEs were obtained from Wu et al. (1995; n=1102) and Litman et al. (2007; n=1612–1880).
*P50.05, **P50.0001 for comparison of SBMA and healthy controls.
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control men and women with a mean age of 6810 years had an
average ambulation of 176m in the timed 2min walk (range
130–237m).
Neurophysiological studies
Nerve conduction study results for 54 SBMA subjects are sum-
marized in Table 5. Ninety-four to 100% of SBMA subjects had
low SNAP amplitude depending on the nerve, and 28 and 52%
had low CMAP amplitudes in the median and peroneal nerves,
respectively.
Fifty-two SBMA subjects had MUNEs done in the abductor
pollicis brevis muscle (Fig. 1). Twenty-four MUNEs were per-
formed in the 14 healthy volunteers (mean age 558 years).
There was a signiﬁcant difference in MUNE between the SBMA
subjects (4723) and the healthy controls (9824) (P50.0001).
Only three SBMA subjects had a MUNE within one standard devi-
ation of the mean control value.
Self-assessment testing
The results of the ADL questionnaire are summarized in
Table 6. The total ADL score is the sum of all nine responses,
Table 5 Neurophysiological studies
MeanSD (range) Reference range Abnormally low (%)
Motor nerve conduction (mV)
Median CMAP 6.33.1 (0.3–13.9) 54.5mV 28
Peroneal CMAP 2.72.0 (0–6.7) 52.5mV 52
Sensory nerve conduction (mV)
Median SNAP 5.43.8 (0–23) 515mV, 510mV over 60 years 98
Ulnar SNAP 3.93.2 (0–16) 515mV, 510mV over 60 years 96
Radial SNAP 5.13.3 (0–13) 515mV, 510mV over 60 years 100
Sural SNAP 1.92.1 (0–8) 56mV, may be absent over 60 years 94
CMAP and SNAP were performed on both sides (n=54). Only right-sided values were used in the correlation and regression analyses (Tables 7 and 8). For the sural
nerve the percent abnormal is for subjects 560 years of age.
Table 4 SBMA patient muscle strength and function
SBMA meanSD
(range)
SBMA percent of
healthy control (%)
QMA (kg)
Shoulder abduction 83 (0–16) 41
Elbow extension 74 (0–19) 38
Elbow ﬂexion 126 (1–32) 48
Wrist ﬂexion 125 (3–26) 54
Hand grip 2210 (6–52) 53
Pinch 52 (2–12) 48
Upper extremity composite [13726 (95–186)
a]** 6625 (18–140) 48
Total upper extremity weight scaled (kg/kg) [1.70.3 (1.2–2.2)
a]** 0.80.3 (0.1–1.5) 47
Hip abduction 166 (3–30) 57
Hip extension 3816 (9–93) 61
Hip ﬂexion 146 (4-33) 70
Knee extension 1711 (3–50) 40
Ankle dorsiﬂexion 137 (0–35) 63
Lower extremity composite [17646 (108–259)
a]** 9841 (28–231) 56
Total lower extremity weight scaled (kg/kg) [2.10.5 (1.2–2.9)
a]** 1.10.5 (0.3–2.4) 52
Total force [31370 (217–445)
a]** 16463 (63–372) 52
Total force weight scaled (kg/kg) [3.80.8 (2.4–5.0)
a]** 1.90.8 (0.7–3.9) 50
Timed 2min walk (m)
Ambulatory with an assistive device 6623 (30–104) 38
Ambulatory without assistive device 13644 (15–208) 77
All timed walks [176 (130–237)
b] 10950 (15–208) 62
The 56 SBMA patients assessed by QMA and timed 2min walk had age and body mass index means of 5310 years and 285kg/m
2, respectively.
QMA values shown for the right side only. For the timed 2min walk, use of an assistive device was optional, and 22 of the 56 subjects chose to do so.
The timed walk values are the average of three trials for each subject. Composite and total scores are shown in bold.
a MeanSD (range) for 10 healthy male volunteers with a mean age of 516 years and body mass index of 264kg/m
2.
b Normative data reported for a 12 person cohort of men and women with a mean age of 6810 years (Light et al., 1997).
**P50.0001 for comparison of SBMA and healthy controls.
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mean total ADL score was 25.95.0, 72% of the best possible
score. The most affected ADL areas were walking, handwriting,
falling, swallowing and speech (53-70% of the maximal scores).
Only 9 of 56 subjects reported no difﬁculty with falls.
In assessing the quality of life in the SBMA population by the
SF-36v2, we compared the SBMA norm-based scores to those
from a national age-matched male cohort of over 2000 respon-
dents (Ware et al., 2007). The SBMA population reported the
following SF-36v2 components as less than 90% of national
norms: physical functioning (56%), role physical (71%), general
health (85%), social functioning (86%) and vitality (87%).
The PCS and MCS were divergent, with scores of 69% and
102% of the national age-matched norm for men 35–74 years
of age, respectively.
Five components of erectile function were assessed using the
IIEF (n=53). Intercourse and overall satisfaction were most
affected (37 and 46% of maximal). Erectile function was rated
at 47% of maximal and 66% that of healthy controls. Four
of 53 respondents were taking prescription medication for
erectile dysfunction, and there were anecdotal reports of beneﬁt.
The mean total IIEF score was 47% of maximal and 59% that
of healthy control individuals who were not symptomatic for
erectile dysfuction (mean age of 55, n=108–109) (Dinsmore
et al., 1999).
Correlations and multivariate analysis
In patients with SBMA, possible phenotype-modifying variables
other than CAG repeat length have yet to be identiﬁed.
Therefore, we evaluated our phenotypic measures for correlation
with age, disease duration and androgen levels as well as CAG
repeat length (Supplementary Table 1). There was an inverse
correlation between CAG repeat length and weight-scaled QMA
(P=0.04, Fig. 2A). Age at evaluation correlated inversely with
measures of muscle strength and function and neurophysio-
logy: QMA (P=0.03, Fig. 2B), timed 2min walk (P=0.005,
Supplementary Fig. 1B), peroneal CMAP (P=0.005), and average
SNAP (P50.0001). Age also correlated inversely with the total
ADL score (P=0.002, Supplementary Fig. 2B) and the total IIEF
score (P=0.02). Disease duration also correlated inversely with
muscle strength and function, neurophysiological measures
(median and peroneal CMAP), ADL and physical quality of life
(Fig. 2C, Supplementary Figs 1C and 2C, Supplementary Table 1).
In contrast, total testosterone correlated directly with muscle
strength and function, as indicated by QMA and timed 2min
walk (Fig. 2D, Supplementary Fig. 1D). Free testosterone and
dihydrotestosterone showed similar correlations (Supplementary
Table 1). Free testosterone also correlated positively with a
nerve conduction measure, the average SNAP (P=0.006). All
androgens correlated positively with the total ADL score and the
physical functioning component of the SF-36v2 (Supplementary
Table 1, Supplementary Fig. 2D). Androgens did not correlate
signiﬁcantly with total IIEF scores, with or without the inclusion
of individuals using erectile dysfunction medication (data not
included in the table).
Since testosterone levels decrease with age (Orwoll et al.,
2006), and both CAG repeat length and age contribute to changes
in muscle strength and function, we used a multivariate regression
analysis to control for the other variables when assessing the rela-
tionship of repeat length, age and testosterone levels to strength
and function. From the regression analysis, CAG repeat length,
age at evaluation and total testosterone levels were each indepen-
dently associated with strength and ADL in our SBMA cohort
(Table 7). Repeat length and age correlated inversely and total
testosterone correlated directly with strength and ADL. Total
QMA, timed 2min walk, and total ADL scores were signiﬁcantly
associated with CAG repeat length, age and total testosterone,
when corrections for each of the other variables were made.
The total IIEF score was also associated with CAG repeat length
and age. Age was the only variable to signiﬁcantly associate with
the peroneal CMAP, average SNAP and MUNE. Total testosterone
was the only variable with a signiﬁcant association with quality of
life, as measured by the SF-36v2 PCS. As with muscle strength
and ADL, the correlation of total testosterone with quality of life
was positive, i.e. higher total testosterone levels were associated
better physical condition scores on the SF-36v2 questionnaire.
Similar results were obtained when duration of weakness was
substituted for age in the regression analysis (Supplementary
Table 2), except that the associations of CAG repeat length cor-
rected for age were not found with correction for disease dura-
tion. This is consistent with an effect of repeat length on the age
of onset but not on the rate of disease progression. Disease
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Figure 1 The statistical MUNE study was performed on the
abductor pollicis brevis of healthy controls (n=24) and SBMA
patients (n=52). The SBMA subjects tested had a mean
median CMAP of 6.33.1mV. The MUNE data from the
SBMA patients were adjusted to exclude single motor unit
potentials less than 40mV (Lehky et al., 2009). Control subjects
had a mean age of 558 years (42–69 years) and a mean
median CMAP of 9.72.8mV. The control subjects did not
have any small motor unit potential values less than 40mV,
therefore no further adjustment of the MUNE data were
needed.
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muscle strength and function when corrected for repeat length
and total testosterone. Total testosterone was positively asso-
ciated with muscle strength and function when corrected for
repeat length and disease duration, just as it was when corrected
for repeat length and age.
Discussion
SBMA is a rare, debilitating, neurodegenerative disorder with no
effective treatment. Although the cause of SBMA is known,
there are unanswered questions about its natural history and the
factors that determine its clinical course. Information regarding
those prognostic factors and the clinical manifestations of SBMA
may be essential for the design and conduct of future
therapeutic trials.
In the development of a treatment for SBMA, early intervention
may also be important to affect disease progression. The subjects
in our study did not seek medical attention until an average
of 2 years after symptom onset, and there was an additional
3 years from ﬁrst medical evaluation until a clinical diagnosis
of SBMA was made. Increased knowledge about SBMA and its
clinical manifestations, together with increased availability of con-
ﬁrmatory genetic testing, should speed the diagnosis of SBMA.
The principal clinical features of SBMA in this study conﬁrm the
ﬁndings of other retrospective analyses (Kennedy et al., 1968;
Lieberman et al., 2000). Muscle cramps were often reported as
a ﬁrst symptom, but leg weakness, tremor and bulbar involvement
were also common. Sixteen of 50 subjects had no known family
history, which is likely to be due to inheritance through non-
manifesting female carriers.
The weakness affected upper and lower extremities and
proximal and distal muscles similarly. A majority of the patients
Table 6 Self-assessment in SBMA (ranked most to least affected)
Raw SBMA
meanSD (range)
SBMA% maximum
score
Healthy control%
maximum score
SBMA percent of
healthy control (%)
ADL
a (unable to unaffected)
Walking (0–4.0) 2.11.1 (1.0–4.0) 53
Handwriting (0–4.0) 2.41.2 (0–4.0) 60
Falling (0–4.0) 2.61.0 (1.0–4.0) 65
Swallowing (0–4.0) 2.70.9 (1.0–4.0) 68
Speech (0–4.0) 2.80.9 (1.0–4.0) 70
Dressing (0–4.0) 3.10.8 (1.0–4.0) 78
Personal hygiene (0–4.0) 3.10.9 (1.0–4.0) 78
Cutting food and handling utensils (0–4.0) 3.50.7 (1.0–4.0) 88
Quality of sitting position (0–4.0) 3.80.4 (2.5–4.0) 95
Total score (0–36.0) 25.95.0 (15.0–35.5)** 72
Quality of life (SF-36v2)
b (low to high)
Physical functioning (10–30) 16.55.8 (10–30) 29 51 57
Role physical (4–20) 11.45.3 (4–20) 36 50 71
General health (5–25) 15.65.0 (3–25) 43 50 86
Social functioning (2–10) 7.62.4 (2–10) 44 51 86
Vitality (4–20) 11.73.5 (4–19) 45 52 87
Role emotional (3–15) 12.62.9 (3–15) 46 51 90
Bodily pain (2–12) 6.40.8 (4–7) 48 50 96
Mental health (5–25) 19.93.6 (8-25) 49 51 96
Physical component summary (0–100) 34.311.0 (16–58)** 34 50 68
Mental component summary (0–100) 52.211.6 (14–67) 52 51 102
Erectile function (IIEF)
c (low to high)
Intercourse satisfaction (0–15) 5.55.7 (0–15) 37 70 53
Overall satisfaction (2–10) 5.53.0 (2–10) 44 83 53
Orgasmic function (0–10) 5.64.4 (0–10) 56 88 64
Erectile function (1–30) 15.212.5 (1–30) 47 71 66
Sexual desire (2–10) 5.92.4 (2–10) 49 63 78
Total score (5–75) 37.826.2 (5–75) 47 80 59
a SBMA percentages for ADL (n=53) are based on the maximum possible score for each component. **P50.0001 for comparison between SBMA and an unaffected
total score of 36.
b The component scores reported for the SF-36v2 (based on a 4 week-recall period, n=53) are as deﬁned by Ware et al. (2007) and were normalized using the
statistical analysis system coding protocol provided by QualityMetric, Inc. (Lincoln, RI). National normalized scores were obtained from a 1998 survey of U.S. subjects,
and the reported averages were calculated for men 35–74 years of age, weighted according to age and sample number (n=2053–2071) (Ware et al., 2007).
**P50.0001 for comparison between SBMA and age-matched controls.
c The percent max scores for the IIEF (n=53) were adjusted for changes in range, i.e. [(raw mean SBMA score – minimum possible score)/(raw score range) x 100%].
Values for healthy controls with a mean age of 55 years (31–86) asymptomatic for erectile dysfunction were obtained from Dinsmore et al. (1999; n=109).
**P50.0001 for comparison between SBMA and an unaffected total score of 36.
Composite and total scores are shown in bold.
3248 | Brain 2009: 132; 3242–3251 L. E. Rhodes et al.had some asymmetry in muscle strength, and interestingly 69%
of these had greater weakness on the dominant side. Such
dominant-side predominant weakness has been described in
other neuromuscular disorders, particularly facioscapulohumeral
dystrophy, and it may reﬂect asymmetric muscle use.
We found an inverse association between CAG repeat length
and age at evaluation as reported previously (Atsuta et al., 2006).
Androgen levels and strength both correlated inversely with the age
of the subjects in this study. However, after adjusting for age (or
disease duration) and repeat length, serum testosterone still
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Figure 2 (A–D) Correlation of QMA scores with CAG repeat length, age, duration of weakness and total testosterone levels. The
values shown are for total weight-scaled QMA (right plus left).
Table 7 Regression analysis of disease measures relative to repeat length, age and testosterone level
CAG repeat length Age Total testosterone
Muscle function
QMA weight scaled 3.50, P=0.001 3.27, P=0.002 2.88, P=0.006
Timed 2min walk 3.16, P=0.003 3.50, P=0.001 2.30, P=0.03
Neurophysiological
Peroneal CMAP 2.72, P=0.009
Average SNAP 4.96, P50.0001
MUNE 2.36, P=0.02
Self-assessment
Total ADL 2.33, P=0.03 2.85, P=0.007 3.93, P=0.0004
SF-36v2 PCS 3.98, P=0.0002
Total IIEF 2.48, P=0.02 3.10, P=0.003
Results of multiple linear regression analysis, where the signiﬁcance of associations of each variable (CAG repeat length, age, and total testosterone) with the respective
disease measures (muscle strength and function, neurophysiological measures, and self-assessment questionnaires) are shown, as adjusted for the other two variables.
Each cell contains t-test statistics and the corresponding P-value. Only associations that were selected by the stepwise analysis and found to be signiﬁcant (P50.05) are
shown.
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timed 2min walk (Table 7).
In contrast to previous reports, our SBMA subjects had mean
cholesterol and glucose levels similar to a national sample of men
in the same age range, although 53% had elevated cholesterol
and 12% increased fasting glucose levels relative to the laboratory
reference standards (Table 3).
As shown in Tables 4–6, the SBMA population scored consis-
tently lower in functional, physiological, and self-reported quality
of life measures than age-matched healthy controls. SBMA scores
resembled those reported in other impaired populations, e.g. the
timed 2min walk in 12 subjects (7 men and 5 women) with
Parkinson’sdisease (Lightetal.,1997),andtheIIEFscoresin patients
with symptomatic erectile dysfuction (Dinsmore et al., 1999).
The decrease in physical function in SBMA is associated with
lower scores in ADL and quality of life. The activity scores in the
ADL questionnaire were decreased 5%-47% from maximal
(normal). The mean ambulation velocities, both with and without
gait aids, were less than what is normally required to cross a street
in a pedestrian crosswalk (1.2m/s) (http://mutcd.fhwa.dot.gov/
pdfs/2003r1r2/mutcd2003r1r2complet.pdf). The divergence of
the PCS and MCS scores on the SF-36v2 points to the physical
burden of SBMA and indicates the patients’ relatively normal
psychological well being.
Reliable outcome measures will be needed to assess therapeutic
efﬁcacy in future clinical trials of SBMA. In this analysis, we exam-
ined several different measures used to quantify disease related
deﬁcits. Our cross-sectional analysis indicates that the QMA and
timed 2min walk appear promising as feasible, quantitative, and
potentially meaningful measures of clinical status in SBMA. Each
correlated with self-assessed quality of life as indicated by ADL,
SF-36v2 and IIEF scores (Supplementary Table 2). The statistical
MUNE may also be useful as a relatively objective, easily blinded,
physiological biomarker of motor neuron degeneration. Additional
research will be necessary to establish the reliability and sensitivity
of these measures in SBMA, and to deﬁne the clinical course of
the disease prospectively.
Trials of anti-androgen treatment in SBMA have been based on
evidence of efﬁcacy from animal models (Katsuno et al., 2002,
2003; Chevalier-Larsen et al., 2004; Banno et al., 2009). The
animal studies indicate that the toxicity of the mutant androgen
receptor protein in SBMA is ligand-dependent, and that reducing
testosterone levels may be beneﬁcial. However, our ﬁnding that
higher, not lower, testosterone levels are associated with better
muscle strength and function indicates that it may be necessary to
balance the anabolic strengthening effects of androgens against
any potentially deleterious effects of androgen-activated mutant
androgen receptor toxicity, such as can be inferred from the
animal studies. A limitation of this interpretation is that it is
based on a cross-sectional analysis. The therapeutic implications
are best addressed in prospective, randomized clinical trials.
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